| ESI | elastase-specific inhibitor; enzyme substrate inhibitor; epidural steroid injection |
|---|---|
| PTI | pancreatic trypsin inhibitor; persistent tolerant infection; Pictorial Test of Intelligence; placent... |
| STI | Scientific and Technical Information; serum trypsin inhibitor; soybean trypsin inhibitor; systolic t... |
| MAP | malignant atrophic papulosis; mandibular angle plane; maturation-activated protein; maximal aerobic ... |
| MBP | major basic protein; maltose-binding protein; management by policy; mannose-binding protein; mean bl... |
| sex differentiation | Differentiation of male and female tissues and organs during embryogenesis, but after sex determination (sex determination (genetic)). (12 Dec 1998) |
|---|---|
| sex differentiation disorders | Disorders in the differentiation process of gonadal tissues and organs during embryogenesis. (12 Dec 1998) |
| neuronal differentiation | Acquisition during development of specific biochemical, physiological and morphological properties by nerve cells. (18 Nov 1997) |
| differentiation | The distinguishing of one thing or disease from another. (18 Nov 1997) |
| differentiation antigen | Any large structural macromolecule that can be detected by immune reagents and that also is associated with the differentiation of a particular cell type or types. Many cells can be identified by their possession of a unique set of differentiation antigens. There should be no implication that the antigens cause differentiation. (18 Nov 1997) |
| invisible differentiation | Differentiation of the cellular chemical constituents in the embryo prior to cytodifferentiation; sometimes recognizable histochemically. Synonym: invisible differentiation. (05 Mar 2000) |
| echocardiographic differentiation | The processing of a signal so that the output depends upon the rate of change of the input; e.g., it will display changes in amplitude but will reduce the duration of the waveform. (05 Mar 2000) |
| a1-trypsin inhibitor | A glycoprotein that is the major protease inhibitor of human serum, is synthesised in the liver, and is genetically polymorphic due to the presence of over 20 alleles; individuals appropriately homozygous are deficient in a1-trypsin and are predisposed to pulmonary emphysema and juvenile hepatic cirrhosis because of alterations in the amino acid and sialic acid components of the glycoprotein. A1-Antitrypsin also inhibits thrombin. Synonym: a1-trypsin inhibitor, human a1-proteinase inhibitor. (05 Mar 2000) |
| ACE inhibitor | <pharmacology> A group of antihypertensive medications that work by inhibiting an enzyme (angiotensin-converting enzyme) that is important in the regulation of blood pressure. Studies have also indicated that it may help prevent or slow the progression of kidney disease in patients with diabetes. Examples include: captopril, ramipril, enalapril, losartan potassium, bepridil and lisinopril. (12 Mar 1998) |
| aldose reductase inhibitor | <pharmacology> A class of drugs being studied as a way to prevent eye and nerve damage in people with diabetes. Aldose reductase is an enzyme that is normally present in the eye and in many other parts of the body. It helps change glucose (sugar) into a sugar alcohol called sorbitol. Too much sorbitol trapped in eye and nerve cells can damage these cells, leading to retinopathy and neuropathy. Drugs that prevent or slow (inhibit) the action of aldose reductase are being studied as a way to prevent or delay these complications of diabetes. (09 Oct 1997) |
| angiotensin-converting enzyme inhibitor | <pharmacology> A class of drugs used in the treatment of hypertension and heart failure. They exert their haemodynamic effect mainly by inhibiting the renin-angiotensin system and produce a reduction of peripheral arterial resistance. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. (14 Aug 2000) |
| aromatase inhibitor | Drugs, such as aminoglutethimide, that inhibit aromatase, an enzyme used in the synthesis of oestrogens. (05 Mar 2000) |
| beta-lactamase inhibitor | <pharmacology> Drugs such as clavulanic acid, which are used to inhibit bacterial beta-lactamases; often used with a penicillin or cephalosporin to overcome drug resistance. (05 Mar 2000) |
| Bowman-Birk inhibitor | A polypeptide that will inhibit both trypsin and chymotrypsin. (05 Mar 2000) |
| C1 esterase inhibitor | An a2-neuraminoglycoprotein that inhibits the enzymatic activity of C1 esterase, the activated first component of complement. A deficiency of this inhibitor results in a lack of inhibition of C1r and C1s leading to uncontrolled activation of the complement cascade and oedema. (05 Mar 2000) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|